{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T03:34:16Z","timestamp":1777865656689,"version":"3.51.4"},"reference-count":31,"publisher":"China Science Publishing & Media Ltd.","content-domain":{"domain":["engine.scichina.com"],"crossmark-restriction":false},"short-container-title":["ABBS"],"published-print":{"date-parts":[[2026,4,1]]},"DOI":"10.3724\/abbs.2026072","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T09:34:44Z","timestamp":1776418484000},"update-policy":"https:\/\/doi.org\/10.1360\/scp-crossmark-policy-page","source":"Crossref","is-referenced-by-count":0,"title":["Metabolic reprogramming promotes AR-V7 splicing via                     SRSF2 lactylation in castration-resistant prostate cancer"],"prefix":"10.3724","author":[{"given":"Wenkai","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingran","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesur","family":"Batur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenda","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mierxiati","family":"Abudurexiti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dingwei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2026","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"CITATION1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","volume":"84","author":"Bergengren O","year":"2023","unstructured":"Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, Bray F. 2022 update on prostate cancer epidemiology and risk factors\u2014a                         systematic review. Eur Urology, 2023, 84: 191-206.","journal-title":"Eur Urology"},{"key":"CITATION2","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.3390\/cancers14174189","volume":"14","author":"Mosillo C","year":"2022","unstructured":"Mosillo C, Calandrella ML, Caserta C, Macrini S, Guida A, Sirgiovanni G, Bracarda S. Targeted approaches in metastatic castration-resistant prostate                         cancer: which data?. Cancers, 2022, 14: 4189.","journal-title":"Cancers"},{"key":"CITATION3","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccell.2019.01.008","volume":"35","author":"Cato L","year":"2019","unstructured":"Cato L, de Tribolet-Hardy J, Lee I, Rottenberg JT, Coleman I, Melchers D, Houtman R. ARv7 represses tumor-suppressor genes in castration-resistant                         prostate cancer. Cancer Cell, 2019, 35: 401-413.e6.","journal-title":"Cancer Cell"},{"key":"CITATION4","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/s41571-018-0085-0","volume":"15","author":"Paschalis A","year":"2018","unstructured":"Paschalis A, Sharp A, Welti JC, Neeb A, Raj GV, Luo J, Plymate SR. Alternative splicing in prostate cancer. Nat Rev Clin                             Oncol, 2018, 15: 663-675.","journal-title":"Nat Rev Clin                             Oncol"},{"key":"CITATION5","doi-asserted-by":"publisher","first-page":"11428","DOI":"10.1073\/pnas.1902651116","volume":"116","author":"Abida W","year":"2019","unstructured":"Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, Cieslik M. Genomic correlates of clinical outcome in advanced prostate                         cancer. Proc Natl Acad Sci                             USA, 2019, 116: 11428-11436.","journal-title":"Proc Natl Acad Sci                             USA"},{"key":"CITATION6","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1001\/jamaoncol.2017.3588","volume":"4","author":"Fox JJ","year":"2018","unstructured":"Fox JJ, Gavane SC, Blanc-Autran E, Nehmeh S, G\u00f6nen M, Beattie B, Vargas HA. Positron emission tomography\/computed tomography-based                         assessments of androgen receptor expression and glycolytic activity as a                         prognostic biomarker for metastatic castration-resistant prostate cancer. JAMA Oncol, 2018, 4: 217-224.","journal-title":"JAMA Oncol"},{"key":"CITATION7","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/onc.2016.223","volume":"36","author":"Martin PL","year":"2017","unstructured":"Martin PL, Yin JJ, Seng V, Casey O, Corey E, Morrissey C, Simpson RM. Androgen deprivation leads to increased carbohydrate metabolism                         and hexokinase 2-mediated survival in Pten\/Tp53-deficient prostate cancer. Oncogene, 2017, 36: 525-533.","journal-title":"Oncogene"},{"key":"CITATION8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.canlet.2020.05.007","volume":"485","author":"Wang J","year":"2020","unstructured":"Wang J, Xu W, Wang B, Lin G, Wei Y, Abudurexiti M, Zhu W. GLUT1 is an AR target contributing to tumor growth and glycolysis                         in castration-resistant and enzalutamide-resistant prostate cancers. Cancer Lett, 2020, 485: 45-55.","journal-title":"Cancer Lett"},{"key":"CITATION9","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1158\/1078-0432.CCR-21-4272","volume":"28","author":"Chakraborty G","year":"2022","unstructured":"Chakraborty G, Nandakumar S, Hirani R, Nguyen B, Stopsack KH, Kreitzer C, Rajanala SH. The impact of PIK3R1 mutations and insulin-PI3K-glycolytic                         pathway regulation in prostate cancer. Clin Cancer                             Res, 2022, 28: 3603-3617.","journal-title":"Clin Cancer                             Res"},{"key":"CITATION10","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1158\/0008-5472.CAN-21-2988","volume":"82","author":"Jiang X","year":"2022","unstructured":"Jiang X, Guo S, Wang S, Zhang Y, Chen H, Wang Y, Liu R. EIF4A3-induced circARHGAP29 Promotes aerobic glycolysis in                         docetaxel-resistant prostate cancer through IGF2BP2\/c-Myc\/LDHA signaling. Cancer Res, 2022, 82: 831-845.","journal-title":"Cancer Res"},{"key":"CITATION11","doi-asserted-by":"publisher","first-page":"112033","DOI":"10.1016\/j.celrep.2023.112033","volume":"42","author":"He Y","year":"2023","unstructured":"He Y, Ji Z, Gong Y, Fan L, Xu P, Chen X, Miao J. Numb\/Parkin-directed mitochondrial fitness governs cancer cell                         fate via metabolic regulation of histone lactylation. Cell Rep, 2023, 42: 112033.","journal-title":"Cell Rep"},{"key":"CITATION12","doi-asserted-by":"publisher","first-page":"217070","DOI":"10.1016\/j.canlet.2024.217070","volume":"597","author":"Chen HJ","year":"2024","unstructured":"Chen HJ, Yu MM, Huang JC, Lan FY, Liao HH, Xu ZH, Yu YJ. SLC4A4 is a novel driver of enzalutamide resistance in prostate                         cancer. Cancer Lett, 2024, 597: 217070.","journal-title":"Cancer Lett"},{"key":"CITATION13","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1007\/s00432-022-04371-w","volume":"149","author":"Beier AMK","year":"2023","unstructured":"Beier AMK, Puhr M, Stope MB, Thomas C, Erb HHH. Metabolic changes during prostate cancer development and                         progression. J Cancer Res                             Clin Oncol, 2023, 149: 2259-2270.","journal-title":"J Cancer Res                             Clin Oncol"},{"key":"CITATION14","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1002\/ijc.31165","volume":"142","author":"Gonzalez-Menendez P","year":"2018","unstructured":"Gonzalez-Menendez P, Hevia D, Mayo JC, Sainz RM. The dark side of glucose transporters in prostate cancer: are                         they a new feature to characterize carcinomas?. Intl J Cancer, 2018, 142: 2414-2424.","journal-title":"Intl J Cancer"},{"key":"CITATION15","doi-asserted-by":"publisher","first-page":"129635","DOI":"10.1016\/j.ijbiomac.2024.129635","volume":"260","author":"Yao Y","year":"2024","unstructured":"Yao Y, Chen X, Wang X, Li H, Zhu Y, Li X, Xiao Z. Glycolysis related lncRNA SNHG3\/miR-139-5p\/PKM2 axis promotes                         castration-resistant prostate cancer (CRPC) development and enzalutamide                         resistance. Int J Biol                             Macromol, 2024, 260: 129635.","journal-title":"Int J Biol                             Macromol"},{"key":"CITATION16","doi-asserted-by":"publisher","first-page":"107139","DOI":"10.1016\/j.jbc.2024.107139","volume":"300","author":"Yu J","year":"2024","unstructured":"Yu J, Li S, Cheng S, Ahmad M, Chen C, Wan X, Wei S. Tanshinone analog inhibits castration-resistant prostate cancer                         cell growth by inhibiting glycolysis in an AR-dependent manner. J Biol Chem, 2024, 300: 107139.","journal-title":"J Biol Chem"},{"key":"CITATION17","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.3390\/cancers16142503","volume":"16","author":"Zhou Y","year":"2024","unstructured":"Zhou Y, Zeng F, Richards GO, Wang N. ENO2, a glycolytic enzyme, contributes to prostate cancer                         metastasis: a systematic review of literature. Cancers, 2024, 16: 2503.","journal-title":"Cancers"},{"key":"CITATION18","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1186\/s12885-023-11324-0","volume":"23","author":"Wang H","year":"2023","unstructured":"Wang H, Yang Z, He X, Guo F, Sun H, Xu S, Xu C. Cuproptosis related gene PDHB is identified as a biomarker                         inversely associated with the progression of clear cell renal cell carcinoma. BMC Cancer, 2023, 23: 804.","journal-title":"BMC Cancer"},{"key":"CITATION19","doi-asserted-by":"publisher","first-page":"10016","DOI":"10.1038\/s41467-025-64997-5","volume":"16","author":"Pan YQ","year":"2025","unstructured":"Pan YQ, Han Y, Qian ZY, Zhang XY, Wang TT, Cai ZR, Chen H. A preserved TGF\u03b2 cytostatic response through DLD-mediated                         metabolic modulation undermines anti-TGF\u03b2 therapy in gastric cancer. Nat Commun, 2025, 16: 10016.","journal-title":"Nat Commun"},{"key":"CITATION20","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.ajur.2019.12.003","volume":"7","author":"Mah CY","year":"2020","unstructured":"Mah CY, Nassar ZD, Swinnen JV, Butler LM. Lipogenic effects of androgen signaling in normal and malignant                         prostate. Asian J Urology, 2020, 7: 258-270.","journal-title":"Asian J Urology"},{"key":"CITATION21","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1016\/j.ijbiomac.2022.10.014","volume":"222","author":"Luo Y","year":"2022","unstructured":"Luo Y, Yang Z, Yu Y, Zhang P. HIF1\u03b1 lactylation enhances KIAA1199 transcription to promote                         angiogenesis and vasculogenic mimicry in prostate cancer. Int J Biol                             Macromol, 2022, 222: 2225-2243.","journal-title":"Int J Biol                             Macromol"},{"key":"CITATION22","doi-asserted-by":"publisher","first-page":"e10733","DOI":"10.1002\/advs.202510733","volume":"13","author":"Li J","year":"2026","unstructured":"Li J, Xun W, Wang X, Luo R, Hu Q, Zhou Z, Yuan J. Lactylation enhances the activity of lactate dehydrogenase a and                         promotes the chemoresistance to cisplatin through facilitating DNA                         nonhomologous end junction in lung adenocarcinoma. Adv Sci, 2026, 13: e10733.","journal-title":"Adv Sci"},{"key":"CITATION23","doi-asserted-by":"publisher","first-page":"e2300694","DOI":"10.1200\/PO.23.00694","volume":"8","author":"Ang D","year":"2024","unstructured":"Ang D, Chan J, Ong WS, Tan HS, Ng QS, Yuen J, Chen K. Androgen receptor splice variant 7 in asian patients with                         metastatic castration-resistant prostate cancer. JCO Precis Oncol, 2024, 8: e2300694.","journal-title":"JCO Precis Oncol"},{"key":"CITATION24","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1038\/s41419-024-07246-9","volume":"15","author":"Li J","year":"2024","unstructured":"Li J, Qiu H, Dong Q, Yu H, Piao C, Li Z, Sun Y. Androgen-targeted hsa_circ_0085121 encodes a novel protein and                         improves the development of prostate cancer through facilitating the                         activity of PI3K\/Akt\/mTOR pathway and enhancing AR-V7 alternative splicing. Cell Death Dis, 2024, 15: 848.","journal-title":"Cell Death Dis"},{"key":"CITATION25","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/1878-0261.13728","volume":"19","author":"Van Goubergen J","year":"2025","unstructured":"Van Goubergen J, Pe\u0159ina M, Handle F, Morales E, Kremer A, Schmidt O, Kristiansen G. Targeting the CLK2\/SRSF9 splicing axis in prostate cancer leads                         to decreased ARV 7 expression. Mol Oncol, 2025, 19: 496-518.","journal-title":"Mol Oncol"},{"key":"CITATION26","doi-asserted-by":"publisher","first-page":"5157","DOI":"10.1007\/s11010-025-05302-2","volume":"480","author":"Gupta P","year":"2025","unstructured":"Gupta P, Srivastava D, Nayak V, Rao BV, Suseela K, Sharma R, Rajappa SJ. YTHDC1 orchestrates oncogenic splicing via the CLK1-SRSF1                         splicing machinery to regulate castration-resistant prostate cancer                         progression. Mol Cell                             Biochem, 2025, 480: 5157-5172.","journal-title":"Mol Cell                             Biochem"},{"key":"CITATION27","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1002\/cac2.12607","volume":"44","author":"Cai J","year":"2024","unstructured":"Cai J, Song L, Zhang F, Wu S, Zhu G, Zhang P, Chen S. Targeting SRSF10 might inhibit M2 macrophage polarization and                         potentiate anti-PD-1 therapy in hepatocellular carcinoma. Cancer Commun, 2024, 44: 1231-1260.","journal-title":"Cancer Commun"},{"key":"CITATION28","doi-asserted-by":"publisher","first-page":"eady5324","DOI":"10.1126\/sciadv.ady5324","volume":"12","author":"Zhao D","year":"2026","unstructured":"Zhao D, Mo Z, Zhang T, Cai X, Yang Z, Chen D, Zhao J. Lactate derived from cancer-associated fibroblasts promotes                         alternative splicing and castration resistance in prostate cancer. Sci Adv, 2026, 12: eady5324.","journal-title":"Sci Adv"},{"key":"CITATION29","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1038\/s41586-024-07992-y","volume":"634","author":"Li H","year":"2024","unstructured":"Li H, Liu C, Li R, Zhou L, Ran Y, Yang Q, Huang H. AARS1 and AARS2 sense l-lactate to regulate cGAS as global lysine                         lactyltransferases. Nature, 2024, 634: 1229-1237.","journal-title":"Nature"},{"key":"CITATION30","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41556-025-01635-8","volume":"27","author":"Zong Z","year":"2025","unstructured":"Zong Z, Ren J, Yang B, Zhang L, Zhou F. Emerging roles of lysine lactyltransferases and lactylation. Nat Cell Biol, 2025, 27: 563-574.","journal-title":"Nat Cell Biol"},{"key":"CITATION31","doi-asserted-by":"publisher","first-page":"101679","DOI":"10.1016\/j.xcrm.2024.101679","volume":"5","author":"Sun R","year":"2024","unstructured":"Sun R, A J, Yu H, Wang Y, He M, Tan L, Cheng H. Proteomic landscape profiling of primary prostate cancer reveals                         a 16-protein panel for prognosis prediction. Cell Rep Med, 2024, 5: 101679.","journal-title":"Cell Rep Med"}],"container-title":["Acta Biochimica et Biophysica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.sciengine.com\/doi\/pdf\/B95D3C576CCE4C389AF2E0952E36F5F1","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.sciengine.com\/doi\/10.3724\/abbs.2026072","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.sciengine.com\/doi\/pdf\/B95D3C576CCE4C389AF2E0952E36F5F1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T07:10:18Z","timestamp":1777533018000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.sciengine.com\/doi\/10.3724\/abbs.2026072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":31,"URL":"https:\/\/doi.org\/10.3724\/abbs.2026072","relation":{},"ISSN":["1672-9145"],"issn-type":[{"value":"1672-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,1]]}}}